# Cell Source, Inc.

Cell Source, Inc. is an other based in United States.

## Overview

- **Organization type:** other
- **Headquarters:** United States
- **Region:** North America
- **Address:** United States
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

Cell Source, Inc. was incorporated in 2013 as a Delaware corporation with a mission to commercialize a proprietary immune-therapy platform called Veto T cells. The company is led by CEO Dennis R. Brown, who has extensive biotech experience, and its stock trades on the OTC Markets under the symbol CLSO. The company's strategy centers on two lead programs: a hematologic cancer treatment combining Veto T cells with a reduced-intensity bone-marrow transplant, and an autoimmune indication targeting systemic lupus erythematosus. Cell Source has not disclosed significant assets under management or investment deployment, as it is a development-stage biotech firm rather than a capital allocator. Cell Source lacks a disclosed team size, additional offices, or adjacent philanthropic vehicles. Its primary operational event in the last 24 months was its continued clinical development and regulatory filings for the Veto T cell platform (per public filings and OTC Markets disclosures). The structural differentiator is its focus on a single, proprietary cell-therapy platform — Veto T cells — that aims to eliminate the need for immune-suppressing drugs in transplant patients. This narrow, high-risk strategy distinguishes it from more diversified biotech firms.

## Sectors

- Healthcare Services

## Questions

### What is Cell Source, Inc.'s primary business focus?

Cell Source develops immune-therapy treatments using its proprietary Veto T cell platform, targeting blood cancers and the autoimmune disorder systemic lupus erythematosus. The company operates as a clinical-stage biotechnology firm, not as an investment vehicle or family office.

### How is Cell Source, Inc. structured?

Cell Source is a publicly traded Delaware corporation listed on the OTC Markets (CLSO). Unlike a family office, it raises capital through equity offerings and grants, deploying funds into research and clinical trials rather than managing third-party assets.

### Who leads Cell Source, Inc.?

The CEO is Dennis R. Brown, who has led the company since its founding. The firm's leadership is focused on scientific development and regulatory approval for its cell-therapy pipeline (per public filings).

### Does Cell Source have any disclosed investment or deployment activity?

No. Cell Source does not report assets under management or investment deployment. Its activities are centered on clinical-stage drug development, which uses funds raised from public markets and grants for research and operations.

## Related profiles

- [Lightstone Value Plus REIT IV, Inc.](https://altss.com/profile/lightstone-value-plus-reit-iv-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cell-source-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology